DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
TREATMENT DECISIONS: WHAT’S RIGHT FOR YOU?
Resource Guide

FIND YOUR VOICE | BE A PARTNER IN YOUR CARE
- Recognize that you have a role in care decisions.
- Share your treatment goals with your team.
- Educate yourself about DLBCL and stay informed about developing research.
- Explore your clinical trial options.

EXPERT ADVICE FOR NEWLY DIAGNOSED PATIENTS
- Immediately get a referral to a lymphoma specialist.
- Speak up if you have questions or feel something is wrong.
- Bring a family member or friend to your appointments.
- Make a list of questions in advance of your office visits.

SUBTYPES OF DLBCL
- T-cell/histiocyte-rich B-cell lymphoma
- Primary DLBCL of the central nervous system (CNS)
- Primary cutaneous DLBCL, leg type
- Epstein-Barr virus (EBV)-positive DLBCL of the elderly
- DLBCL not otherwise specified (NOS)

TREATMENT CONSIDERATIONS
- Disease-specific factors:
  - Stage and subtype
  - Clinical features
  - Lab test results
- Patient-centered factors:
  - Age and co-morbidities
  - Social and lifestyle factors

DLBCL TARGETED THERAPIES
- Axicabtagene ciloleucel (Yescarta)
- Loncastuximab tesirine (Lonca, Zynlonta)
- Polatuzumab vedotin (Polivy)
- Tafasitamab-cxix (Monjuvi)
- Tisagenlecleucel (Kymriah)
- Selinexor (Xpovio)

VISIT THESE RELATED PROGRAMS
- Expert Advice for Newly Diagnosed DLBCL Patients
- Diffuse Large B-Cell Lymphoma (DLBCL) Treatment and Research News
- Should DLBCL Patients Consider a Second Opinion?
- Is COVID-19 Vaccination Safe and Effective for DLBCL Patients?
- The Pro-Active DLBCL Patient Toolkit
- Office Visit Planners: Patients & Care Partners (printer-friendly)
## Glossary of Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ann Arbor Staging System</strong></td>
<td>The staging system for both Hodgkin lymphoma and non-Hodgkin lymphoma.</td>
</tr>
<tr>
<td><strong>B Cells</strong></td>
<td>Part of a person’s immune system that develop from stem cells in the bone marrow.</td>
</tr>
<tr>
<td><strong>Biomarker</strong></td>
<td>In reference to the measurement of your blood, body fluids, or tissue in order to assess one’s health to determine proper care.</td>
</tr>
<tr>
<td><strong>CHOP</strong></td>
<td>A treatment regimen that includes cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone.</td>
</tr>
<tr>
<td><strong>Double Hit Lymphoma (DHL)</strong></td>
<td>An aggressive type of B-cell non-Hodgkin lymphoma (NHL) characterized by re-arrangements of two genes, the MYC gene and either BCL-2 or BCL-6 gene.</td>
</tr>
<tr>
<td><strong>Fluorescence in Situ Hybridization (FISH)</strong></td>
<td>A chromosome test used to identify specific genes or chromosome changes.</td>
</tr>
<tr>
<td><strong>Flow Cytometry</strong></td>
<td>Analyzes your blood and bone marrow cells in order to classify the cell types and determine your disease risk as well as appropriate treatment plan.</td>
</tr>
<tr>
<td><strong>CAR (Chimeric Antigen Receptor) T-Cell Therapy</strong></td>
<td>Treatment in which the T cells (a type of immune system cell) of a patient are laboratory-altered to attack cancer cells in the body.</td>
</tr>
<tr>
<td><strong>R-CHOP</strong></td>
<td>A treatment regimen that includes rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone.</td>
</tr>
<tr>
<td><strong>Targeted Therapy</strong></td>
<td>A type of personalized medicine that works by blocking specific mutations and by preventing cancer cells from growing and dividing, without affecting normal cells.</td>
</tr>
</tbody>
</table>

## DLBCL Resources
- Cancer.net
- The Leukemia & Lymphoma Society (LLS)
- Leukemia Research Foundation
- Lymphoma Research Foundation

## More Tools for Empowerment
- Digitally Empowered™
- PEN-Powered Activity Guide
- Empowered Blog
- Empowered! Podcast

---

*The Pro-Active DLBCL Patient Toolkit is brought to you by the Patient Empowerment Network. This program is made possible in part by funding provided by Incyte Corporation and MorphoSys, Inc., and through generous donations from people like you.*

---

© 2021 Patient Empowerment Network, a 501(c)(3) Public Charity
www.powerfulpatients.org

Produced by Health Content Collective